Silence Therapeutics (SLN) Total Non-Current Liabilities (2019 - 2024)
Silence Therapeutics recorded quarterly Total Non-Current Liabilities of -$75.3 million in Q3 2024, down 2.53% quarter-over-quarter from -$73.4 million in Q2 2024, and up 0.8% year-over-year from -$74.7 million in Q4 2023.
Silence Therapeutics' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at -$75.3 million for Q3 2024.
- In Q3 2024, Total Non-Current Liabilities rose 0.8% year-over-year to -$75.3 million; the TTM figure through Sep 2024 stood at -$75.3 million (up 0.8% YoY), while the FY2023 annual figure was -$73.2 million, down 193.21% from the prior year.
- Total Non-Current Liabilities came in at -$75.3 million for Q3 2024 at Silence Therapeutics, down from -$73.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $97.7 million in Q4 2021 to a low of -$90.0 million in Q1 2022.
- A 5-year average of -$48.5 million and a median of -$75.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities surged 239.82% in 2020 and plunged 198.35% in 2023, its largest moves.
- Silence Therapeutics' Total Non-Current Liabilities stood at $67.8 million in 2020, then surged by 44.17% to $97.7 million in 2021, then dropped by 23.81% to $74.5 million in 2022, then slumped by 198.35% to -$73.2 million in 2023, then dropped by 2.83% to -$75.3 million in 2024.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered -$75.3 million, -$73.4 million, and -$71.4 million for Q3 2024, Q2 2024, and Q1 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -75.30 Mn |
| Jun 30, 2024 | -73.44 Mn |
| Mar 31, 2024 | -71.42 Mn |
| Dec 31, 2023 | -73.23 Mn |
| Sep 30, 2023 | -75.91 Mn |
| Jun 30, 2023 | -76.21 Mn |
| Mar 31, 2023 | -72.91 Mn |
| Dec 31, 2022 | 74.46 Mn |
| Sep 30, 2022 | -75.40 Mn |
| Jun 30, 2022 | -86.37 Mn |
| Mar 31, 2022 | -89.99 Mn |
| Dec 31, 2021 | 97.73 Mn |
| Sep 30, 2021 | -79.96 Mn |
| Jun 30, 2021 | -87.07 Mn |
| Dec 31, 2020 | 67.79 Mn |
| Jun 30, 2020 | -78.51 Mn |
| Dec 31, 2019 | 19.95 Mn |